Company
Cgenetix
Developing the next generation of non invasive molecular biology diagnostic tool for the clinical monitoring of transplant patient.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Customers
- clinicians
Claim, correct or request removal
Record updated 17 September 2026
About
CGenetix develops the new generation of liquid biopsy biomarkers to evaluate organs damages during a pathological process.
Funding snapshot
- Total raised
- $100KSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Grant, $100K2025-10-28
Funding rounds
- Grant
- $100K2025-10-28, Company stated
Products
- Other
- non invasive molecular biology diagnostic tool for the clinical monitoring of transplant patient
Loading relationship preview